For 'Defining the role of authors and contributors', 'Disclosure of financial and non-financial relationship and activities, and conflict of interest', and 'Responsibility in the submission and peer-review process' see Our Policies
Haematologica is the main tool through which the Ferrata-Storti Foundation, a non-profit organization, promotes the dissemination of new knowledge in the field of hematology. A high quality of articles, immediate free access to everything published and the lowest possible cost for authors are the principles that inspire Haematologica management.
Haematologica considers for publication manuscripts on physiology and pathophysiology of hematopoiesis and blood cells as well as clinical studies on disorders that hematology departments take care of. Papers that focus primarily on disorders of vessels, atherosclerosis included, are outside the scope of Haematologica and will not be considered for publication.
Haematologica does not publish the results of studies that have already been published, even partially, or are going to be published in any form. Meeting abstracts and manuscripts released as a preprint before or during submission are the only exception.
Preprint is allowed under these conditions:
- Once published in Haematologica, it is the author’s responsibility to ensure that the preprint record is updated with a publication reference, including the DOI and a URL link to the published version of the article on the Haematologica website.
- The preprint must not be modified while the manuscript is under evaluation and cannot be updated if the manuscript is accepted for publication in Haematologica.
- Preprints, as well as any related public comments, will be considered in the evaluation of the manuscript submitted to Haematologica.
- The existence of a preprint must be explicitly stated in the submission form and in the cover letter for the submission.
- A PDF of the preprint must be included in the submission as a supplementary file.
Haematologica does not even consider for publication papers not reporting primary data whose preparation has been promoted, sponsored or supported in any way by a company whose product is discussed in the paper. Potential conflicts of interest of single authors are not considered an obstacle for publication (all authors are required to disclose competing interests during the online submission process).
Original articles. There is no limit to the number of authors, but this must be commensurate with the complexity of the study. The manuscript are to be divided into sections under the following subheadings: Abstract, Introduction, Methods, Results, Discussion, and References.
- Abstract (unstructured), maximum 250 words. Articles reporting clinical trials should provide the trial registration number at the end of the abstract. Use abbreviations only for terms that occur at least twice. In this case, explain their meaning when they are first used.
- Main text (Introduction, Methods, Results, Discussion) maximum 4,000 words. The Methods and Results sections can be divided with specific subtitles. The methods section (maximum 500 words) should include the most important methods that allow readers to understand the article content. When required, further information on methodology can be provided in the Supplementary data.
- References, maximum 50.
- Figure and Tables, maximum 8 items in total. Additional figures and tables can be published as Supplementary data.
Original articles reporting randomized trials must follow CONSORT recommendations, meta-analyses and guidelines PRISMA recommendations, observational studies STROBE recommendations, and studies of diagnostic accuracy STARD guidelines.
Review articles. As a rule, Reviews are by invitation. However, authoritative researchers can submit reviews on topics for which they have demonstrated competence. The maximum number of authors is usually limited to three. Review articles are maximum 5,000 words long (excluding abstract, tables, figure legends and references) and do not have a specific structure. The reviews should contain an unstructured abstract of maximum 250 words (abbreviations only for terms that occur at least twice), and have a maximum 100 references. Authors are encouraged to describe the methods used for locating, selecting, extracting, and synthesizing data; this is mandatory for systematic reviews (see PRISMA guidelines). The use of tables and figures is strongly encouraged (no limit to their number).
Perspective articles. The format and editorial guidelines for this type of article are the same as for the reviews. The perspective articles differ from the reviews because they do not require a systematic and exhaustive analysis of the literature, but allow authors to use literature data to freely express their personal opinion on topics and controversies relevant to hematology.
Editorials. Editorials that comment on Haematologica articles are by invitation and are published in the same issue as the commented paper. However, submission of Editorials by authoritative researchers on debated topics or important news is welcome.
Editorials have a free structure (no abstract), contain about 1,500 words (excluding tables and references), up to 20 references and may contain two display items (figures and/or tables). No more than two authors are permitted.
Guideline articles. They should produced by an international group of experts. These articles are up to 5,000 words long (excluding tables, figure legends and references), and the authors are free to give the text the structure that best suits their purposes. The articles should contain an unstructured abstract of maximum 250 words, can include all the figures and tables that the authors deem necessary, and have a maximum 100 references. We recommend following the PRISMA recommendations for this type of studies.
Letters to the Editor. This type of article is dedicated to the publication of original data that can be reported and discussed in no more than 1,500 text words (excluding tables, figure legends and references). Letters have no abstract, no headings, a maximum of three tables and/or figures, and no more than 15 references. Letter should start with a paragraph summarizing the rationale for the study and the major conclusions. When appropriate, the reporting recommendations detailed for Original articles should be followed. Letter can use Supplementary data for three additional figures and/or tables. The use of text in Supplementary data is not foreseen except for the legends of the figures and the titles of the tables (no Methods).
Case Reports & Case Series. Reports of special cases that contribute to a better understanding of hematological diseases or to patient care will be considered for publication. These reports need to be conclusive and must include pathogenetic insights in addition to the description of the clinical case(s). Only few Case Reports can be published and a strict selection is in place. Case Reports have no abstract, no headings, and a maximum of 1,500 words in the text (excluding tables, figure legends and references), a maximum of three tables and/or figures, and 15 references. Supplementary data can't be used.
Comments. This format is used to discuss a recently published article in Haematologica, or to discuss cutting edge ideas or developments in the broad field of hematology. Papers containing new data can not be published with this format. Comments have no abstract, a maximum of 1,000 words in the text and 10 essential references. Comments should not include figures or tables. Please start the comment with a paragraph summarizing the rationale for the comment, citing the article or articles that form the basis for the comment. No more than two authors are allowed.
We are very flexible on the format of the first submission and the rules described in the following sections do not necessarily all have to be respected .
At initial submission, only two PDF files will be requested:
- One pdf file with the text, tables, and figures (please, make sure the file size is below 5 Mb)
- One PDF file with all supplementary data
A revised manuscript must comply with all the editorial rules. The following files will be requested:
- One word document with text and tables (indicate in color the changes that were made compared to the first submission)
- One high quality file for each figure
- One pdf file with all supplementary data
- In case of changes in the authorship, please fill this form and submit it as supplemental file: Change of Authorship Form
Manuscripts should be prepared according to the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations).
Manuscripts should be prepared using American English spelling. Scientific nomenclature should be used without Saxon Genitive (for example: use 'Hodgkin Lymphoma' and not 'Hodgkin's Lymphoma').
Abbreviations and acronyms should be used when a term that includes multiple words is used more than once in the Abstract and more than three times in the Main text. Abstract, Main Text and Figure legends should be considered as a separate entities and abbreviations must be explained in full text in all these items. Abbreviation and acronyms used in Tables must be explained in a note below the Table. Abbreviations should not be used in the title unless the abbreviation is better understood than the full designation, such as for DNA, which is more easily understood than Deoxyribonucleic acid. If this is the case, explain the abbreviation in the Abstract. Abreviations should not be written in the plural form.
Units and measurements. Use the SI system of units. Failure to use SI system in the figures requires that the authors redo them.
Drugs. Commercial names of drugs have to be avoided. Drugs should have be referred to under their generic names unless different proprietary versions are being discussed.
Genes and proteins. Use the official gene symbols when referring to genes, transcripts, proteins. (for example: Use ABL1, not ABL or c-ABL ; use MYC, not c-Myc). Use this database as a reference: http://www.ncbi.nlm.nih.gov/sites/entrez?db=gene. Human Genes' names have to be indicated in italic and capital, Human Proteins' names only in capital letter. Mouse and Rat Genes' names have to be indicated in italic, with only the first letter in capital and the remaining letters in lowercase (Shh). Mouse and Rat Proteins' names have to be indicated only in capital letter (SHH). Zebrafish and Frog (xenopus sp.) Genes' names have to be indicated in italic and all in lowercase (shh). Zebrafish and Frog (xenopus sp.) Proteins' names must have the first letter in capital and the remaining letters in lowercase.
Protection of human individuals in research. When reporting studies (prospective or retrospective) involving people, medical records, and human tissues, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008. Authors should also declare that any research involving people, medical records, and human tissues was approved by the relevant institutional review boards or ethics committees and that all human participants gave written informed consent (Haematologica reserves the right to ask the authors or the institution they indicated for a copy of the document). Patients have a right to privacy that should not be violated. Identifying information, including names, initials, or hospital numbers, should not be published. Photographs and any data that can lead to patient identification can be published only if this is essential for scientific purposes and the subject has signed a specific written informed consent.
Protection of animals in research. When performing experiments on animals or animal tissues, authors should seek approval by an institutional ethics committee and should strictly follow the institutional and national guide for the care and use of laboratory animals. We can only consider manuscripts reporting on studies on animals or animal tissues if ethical committee approval of the study can be documented.
Clinical trials. We request, as a condition for publication, the registration of all clinical trials in a public trials registry. The ICMJE provides specific guidelines on this topic. The ICMJE defines a clinical trial as any research project that prospectively assigns human subjects to intervention or concurrent comparison or control groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Medical interventions include drugs, surgical procedures, devices, behavioral treatments, process-of-care changes, and the like. Haematologica does not advocate one particular registry, but follows the ICMJE recommendations. Because it is critical that trial registries are independent of for-profit interests, the ICMJE policy requires registration in a WHO primary registry rather than solely in an associate registry, since for-profit entities manage some associate registries.
Manuscripts must have the following sequence of items:
- Title page
- Main text
- Figure legends
Information provided on the title page should correspond exactly with the information provided in the online system for submission.
Title. The title should consist of a phrase or a sentence; question forms should be avoided. Capitalize the first letter of the sentence only, and try not to use abbreviations. In the event that abbreviations are used because they are very easily understood, they must be spelled out in the abstract. Abbreviation of study group names may be presented in the title if they are expanded in the abstract. All members’ names should be listed in an appendix and presented at the end of the main text. In this case, include a title page note that refers to that appendix.
Authors. Names of authors should be presented as full first name, initial of middle name (if applicable) and last name. Number authors’ affiliation in superscript. Do not include professional titles or abbreviations of qualifications or positions held.
Haematologica does not limit the number of authors of original articles, letters, guidelines and case reports. However, it must be proportionate to the complexity of the data presented, and the editor will ask for a reduction of the number of authors if does not seem justified. See above Types of articles for the maximum number of authors for the other types of articles.
Authors' contribution. If more than one author contributed equally to the work as 'principal investigator' (first name) or 'senior' author (last name), a statement of equal contribution can be placed here. Use authors’ initials rather than full names, e.g. 'GGH and FS co-first authors'. In the list of authors, use an asterix (*) before the name of authors to indicate sharing the position of first author, a hash (#) for last position. An high number of authors contributing equally is discouraged. In case 'equal contribution' as principal investigator is attributed to more than three authors and 'senior author' to more than two people, please explain the reason for this anomaly in the accompanying letter. In the rare cases in which all authors contributed equally, their names must appear in alphabetical order.
Information of contribution to the manuscript of each author should be provided during online submission.
Affiliations. The authors’ affiliations should be provided on a new line immediately after the authors’ names with every affiliation on a new line. Every affiliation on a new line. Provide only city, state (abbreviated) and country, for USA affiliations and not full address. Proviede the postal code only in case it is required for the identification of the institution.
Running heads. Please provide a shortened title as running head of maximum 50 characters. The use of acronyms and abbreviations is permitted.
Corresponding author. Indicate the name and email address of the author who is in charge of managing the correspondence.
Data sharing statement. It is highly recommended that the authors make their original data and protocols available to other investigators without unreasonable restrictions. It is therefore required that the authors indicate if and how these data can be obtained. This information will appear at the end of the manuscript.
Word count. Provide a separate word count for the abstract and the main text (= introduction + methods + results + discussion). Indicate how many tables and figures are present in the manuscript. Indicate how many supplementary files are associated with the manuscript (we request one PDF file for all supplementary data; only in specific circumstances, as submission of movies or Excel tables, we accept more than one PDF file).
Trial registration. Confirmation and details of trial registration should be given on the first page; please use the following form: 'ClinicalTrials.gov identifier: NCT00123456'
Acknowledgments. If applicable, indicate secretarial and editorial assistance, technical and intellectual input and advice, fellowships, funding and grants. The form to be used is 'The authors would like to thank...'. For all types of financing (e.g., governmental, industrial, personal sources) it is recommended to report the identifiers and indicate which authors received the grant (This investigation was supported by the grant DKxxxx to AB from the National Institutes of Health, USA).
A summary (unstructured) of 250 words is required only for Original articles, Reviews, Perspectives, and Guidelines. Do not include references. See Manuscript style for abbreviations and acronyms.
See above Type of articles for word limits and Manuscript style for other editorial requirements.
Subheadings. In the types of articles that require structuring of the main text in different sections, we discourage the use of more than one level of subheadings within each section. The style of the different subheadings levels must be consistent.
Authors must take great care of the accuracy of citations in the text and corresponding references. Accuracy is very important because references will be linked to Medline and other online database, and these links do not work if citation information is not completely accurate.
Every citation needs a reference, and every reference must correspond to a citation. Authors must take care that this also occurs in revised papers, in which references are often moved, added or deleted.
If you use citation software, please check carefully to ensure that it formats references according to Haematologica rules. You can download the reference style to be used by Endnote
10.1. Citations of bibliographic references must be numbered consecutively in the order in which they appear the first time in the text. Figure and Tables do not have an independent numbering sequence but follow the logic of the reading sequence. So, the numbering of references appearing for the first time in tables and figures depends on where the diction Figure x or Table y is used for the first time in the main text.
In the text, cite references by inserting the superscripted reference number:
- Melick5 reported IDH1 mutations in AML.
- Melick and Brown5 reported IDH1 mutations in AML.
- Melick et al5 reported IDH1 mutations in AML.
- Several groups reported the presence of IDH1 mutations in AML.5-9
- Two studies reported IDH1 mutations in AML.5,6
- Melik et al5 identified IDH1 mutations in AML while Brown10 did not.
Never refer to the number of the reference
- For a review, see Melick et al11 (Not: For a review, see 11)
10.2. Citation of Figures and Tables. References to Tables and Figures in the same article should be presented in brackets and should specify 'Table' or 'Figure' and the relevant identification number. When reference is made to more than one Table or Figure, please follow these examples: Figures 1 and 2; Tables 1 and 3; Figures 2-4 and 6; Tables 2, 4 and 6. References to Figure panels and subpanels should be presented by adding a capital letter in alphabetic order immediately after the identification number (for example: Figure 1A, Figure 1B). When reference is made to more than one Figure panel or subpanel, follow these examples: Figure 2B and C ; Figure 3B-D). For references to Figures, Tables or Movies in Supplementary data, add an S to the number of Figure-Table-Movy (e.g. Movie S1).
10.3. Citations only in the text. Any data or information not yet published in any way should not be referenced and should be mentioned in the text in parentheses. Written permission for the reference to be made must be obtained from the person concerned, a copy of which may be requested by the journal. Submitted papers follow the same rules.
(Desmopressin reduced bleeding time in a mouse model of Scott syndrome. G. Rossi, University of Pavia, email, 20 August 2020).
10.4. Reference list. Place References after Main text. Haematologica adopted the recommendations of the International Committee of Medical Journal Editors (ICMJE) for the style of the references. So, the titles of journals should be abbreviated according to the style used for MEDLINE.
In short, follow these guidelines:
- Journal article with 6 or less than 6 authors: list all authors.
Silvestri L, Pagani A, Nai A, De Domenico I, Kaplan J, Camaschella C. The serine protease matripase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Met. 2008;8(6):502-511.
- Journal article: with more than 6 authors: list the first 3 authors followed by 'et al.'
Diop F, Moia R, Favini C, et al. Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. Haematologica. 2020 ;105(2):448-456.
- Prepublished journal article: indicate the date on which the article was published online and report the DOI (digital object identifier).
Hermand P, Azouzi S, Gautier EF, et al. The proteome of neutrophils in sickle cell disease reveals an unexpected activation of interferon alpha signaling pathway. Haematologica. 2020 Mar 5. doi: 10.3324/haematol.2019.238295. [Epub ahead of print]
- Journal article in press: use the phrase 'In press.' instead of year, volume number, and page numbers
Hermand P, Azouzi S, Gautier EF, et al. The proteome of neutrophils in sickle cell disease reveals an unexpected activation of interferon alpha signaling pathway. Haematologica. In press.
- Personal communication, submitted article, unpublished data: see above 10.3. Citations only in the text.
- Book: indicate Author(s)/Editor(s), Title, Type of Medium, Edition, Editor, Place of Publication, Publisher, Date of Publication. See International Committee of Medical Journal Editors (ICMJE) for more details.
Iverson C, Flanagin A, Fontanarosa PB, et al. American Medical Association manual of style. 9th ed. Baltimore (MD): Williams & Wilkins; 1998.
- Book chapter: indicate Author(s) of the chapter, Title of the chapter, Book Information.
Whiteside TL, Heberman RB. Effectors of immunity and rationale for immunotherapy. In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC Jr, Gansler TS, Holland JF, Frei E 3rd, editors. Cancer medicine 6. Hamilton (ON): BC Decker Inc; 2003. p. 221-8.
- Published abstract: indicate Author(s), Title and indication of where the abstract was published.
Manni S, Carrino M, Fregnani A, e al. Protein kinase CK1 alpha inhibition causes mantle cell lymphoma cell apoptosis. Haematologica 2018;103(s3):abstract 829.
- Online document: indicate Author(s) or any Institutional author, document title, the URL, and the date on which it was accessed.
Jablonski S. Online Multiple Congenital Anomaly/Mental Retardation (MCA/MR) Syndromes. https://apps.who.int/iris/bitstream/handle/10665/44796/9789241503082_eng.pdf?sequence=1&isAllowed=y Accessed 4 April 2020.
The maximum number of figures and tables is indicated above in Types of articles.
The authors are strongly encouraged to insert in the main text only the Tables and Figures that are essential to understand the meaning of their study, placing the other data (as patient characteristics and primer sequences) in the Supplementary data when this is allowed for that type of article.
For the first submission of the manuscript, it is only required that Figures and Tables are easy understandable. For subsequent submissions, however, Figures and Tables are required to exactely comply with all specific editorial rules. Failure to comply with these rules causes non-acceptance of the paper independently form its scientific merit.
11.1. Figures. Figures must be in JPG, PNG or PDF. Files of color figures should be submitted as RGB (red/green/blue; not CMYK).
Recommended resolution is 600dpi.
Figures can be of two dimensions in terms of width:
- 8 cm (1920 pixels) for one column figures
- 16 cm (3840 pixels) for two colums figures
11.1.2. Line art figures (graphs, scatter plots, diagnostic algorithms, flowcharts and other types of text-based figures). A common problem of this type of figures is that the entered text is written in too small characters and is difficult to read. Many readers of Haematologica use tablets or even smartphones to read the journal and, consequently, the optimal dimensions of the writings are those that allow their easy reading even on small screens. As a simple general rule, we suggest that Authors prepare their line art figures 8 cm (1920 pixels) wide or 16 cm wide (3840 pixels), and print them in their original size: the font sizes are correct in case all the writings are readable very easily. Even if differences in readability of different fonts do not allow us to provide precise indications, we advise against the use of fonts smaller than 8 pt or larger than 12 pt. Make sure that the thickness of the lines is such as to make them easily visible when printing the figure.
11.1.3. Images. Changes introduced in digital images to improve readability can result in incorrect information. It is therefore recommended to avoid any type of image retouching. However, if the authors deem it essential to modify the image, the changes must be applied to the whole figure and not to single portions. Linear changes in contrast, brightness or color must be applied equally to all parts of the image. Contrast and brightness should not be increased to such an extent that parts of the image disappear.
Authors must include scale bars in any microscopy images of cells or tissue. Staining techniques must be reported in legends.
Electrophoretic gels and blots should have full tonal range to avoid loss of data and should contain at least one molecular weight marker. Avoid as much as possible to build a figure by assembling lanes from different sections of one or more gels. If this is unavoidable, borders must be easily identifiable or marked and the legend must explain how the figure was built.
Authors may also be asked to provide the original figures not retouched nor cropped for review.
11.1.4. Complex, multipanel figures. Multi-paneled figures must be supplied as one file, with each panel clearly labeled. Avoid giving a header to each panel, but give this information in the figure legend. Size and style of letters and labels of different panels must be uniform within each figure and, whenever possible, between figures. The choice to reduce the number of figures by creating complex panels with a number of items is discouraged. We suggest not to insert more than 6, simple panels for each figure. As a rule, the figures are to be published on a single page and exceptions to this rule must be approved by the Editor. Please, consider to place very large Figures in Supplementary data when this is allowed for that type of article.
The figure below has only 4 panels, but it contains too many items, which are not always clearly indicated. The writings have too small characters and are difficult to read even when the image is displayed as a full page on a large monitor. Furthermore, similar writings have different characters both in size and type. Figures of this type discourage the reader from reading (and therefore citing) the article.
The figure below also has 4 panels, but it is well organized, the writings are readable even on a small screen and each item is easily identifiable. This type of figure attracts readers.
11.1.5. Reproductions and adaptations. The author must obtain written permission for the reproduction and adaptation of material that has already been published. Permission should be obtained from the copyright holder or publisher. Before a manuscript is accepted, Haematologica will need to receive a copy of the written permission. All material presented from other sources should be identified and should be accompanied by a specific reference in the legend confirming that permission for its use had been obtained, for example: 'Adapted from Berger et al. Leukemia 2003, 17, 1820-1826; with permission.'
11.1.6. Legend to figures. Legends should should contain a title (in bold) and sufficient details to make the figure easy to understand. When a figure contains multiple panels, the legend needs to start with a first sentence as an overall title for the entire figure and the rest of the text as the explanation of the figure panels. For the references that appear for the first time in a legend, see above 10.1. Citations of Bibliographic references.
All abbreviations, acronyms and symbols in each figure should be explained in the legend regardless of whether this was done in the main text.
11.1.7. Videos. We recommend the format MP4. In case MP4 is not available, we accept MOV and AVI. Videos must be no larger than 10MB. For optimal compatibility across operating systems and devices, please select H.264 compression when saving.
11.2. Tables. As for figures, consider the possibility to place non essential Tables in Supplementary data when this is allowed for that type of article. This is particular important for very large Tables that take up more than one page. Provide tables in a simple format, without specific layout. The final arrangement will be given by journal staff at time the final manuscript PDF file is prepared. Anyway, structure the table so that it can be inserted into the page in its normal vertical orientation (to avoid having to rotate the page to read the table). Tables should have a short and clear title. Provide a legend to the table (if needed) directly below the table. Explain in the legend all abbreviations, acronyms and symbols that are used in the table.
Prepare one single PDF file containing all supplementary data (supplementary methods, supplementary results, supplementary figures, supplementary tables). Supplementary data has its own reference list. Everything that is included in the Supplementary data must comply with editorial rules. Please consider that we will not modify in any way what is included in the PDF and that failure to comply with editorial rules does not allow us to publish the article. Whenever possible, keep the PDF size below 30 MB. Additional files that can not be incorporated in the PDF file (such as video, large excel tables running over several pages, etc.) have to be provided separately
13.1. Submission fee. A nonrefundable fee of 70 Euro (including VAT) is due on submission for all uninvited papers with the only exception of Guidelines and Comments.
13.2. Publication charge.
- Original articles, Reviews and Editorials. Manuscript submitted before July 1, 2020: € 1,600 (plus VAT when needed), afterwards: € 2,000 (plus VAT when needed).
- Letters and Case reports. Manuscript submitted before July 1, 2020: € 350 (plus VAT when needed), afterwards, 2020: € 400 (plus VAT when needed).
- Guideline Articles, Comments, as invited Reviews, invited Perspective articles and invited Editorials. Free of charge.
During submission, authors are asked to disclose any potential conflict of interest by filling in a form prepared by the International Committee of Medical Journal Editors. For information on conflict of interest, see Disclosure of financial and non-financial relationship and activities, and conflicts of interest in Our Policies
Submitted articles undergo the regular revision process which, in the event the manuscript does not undergo a quick rejection, allows a first response (accepted, minor changes, major changes) in 3-4 weeks. In rare cases, the Editor can accept the authors' request that the manuscript follow an accelerated procedure (Fast-track).
14.1. Regular submission. Go to Submit a manuscript and follow the instructions.
Be ready to submit the files indicated in Section 3. Different requirements for first submission and revised manuscript.
For Revised manuscripts, make sure that all changes are in color (do not use 'track changes'). Moreover, be ready to provide a detailed description of all changes made in the main manuscript in response to the questions/remarks of the reviewers. For preparing this document, copy and paste each question/remark of the reviewers and provide a short answer on how this question/remark has been addressed in the revised manuscript. The description of changes can be copied and pasted into a text box during online submission. If figures or tables need to be included in the answers to the reviewers, a PDF file with that information can be uploaded as a supplementary file.
Please, consider that the author names and affiliations inserted in the online submission system will be those that will appear in PubMed soon after pre-publication. The Haematologica Journal staff is therefore not responsible for eventual inaccuracies or mistakes in the affiliations inserted during the submission process. Please, also note that the affiliations that will appear in PubMed after the final publication of the paper will be those ones indicated by the authors during the proofreading and they will replace the ones appeared as pre-publication
Before resubmitting a manuscript that has been modified according to reviewers' suggestions, carefully check that all content, including Results, Tables and Figures, is correct. If accepted, your manuscript will be pre-published exactly as it is. Moreover, what is contained in the pre-published manuscript will be used for producing the final version of your article that will be inserted in an issue of the journal. Please, take note that the data cannot be changed during the production process and their correction requires publication of an erratum in the following issue of the journal.
14.2. Fast-track review. Manuscripts (Original articles) reporting results that promise to substantially change clinical practice or the current view of biological processes associated with blood diseases can be selected for fast-track review. These papers will receive an initial decision within 1 week. We can only select a few articles for fast track, as this requires extra efforts of our reviewers and editors. Thus, these manuscripts will be selected by the editors. Authors can request fast-track review by e-mail: please send the manuscript as PDF file with an accompanying explanation why rapid review should be considered to: firstname.lastname@example.org
All manuscripts submitted to Haematologica are critically revised in accordance with the principles of Peer Review of JCMJE. Each paper is first evaluated by one or more editors, who will assess the overall quality and novelty of the work and the article's appropriateness for the scope of Haematologica. Articles that are not found to be relevant for Haematologica will not be send out for external review and will be returned to the authors. The remaining articles are reviewed by external referees. We aim to provide feedback to the authors in less than 4 weeks after submission (1 week for Fast track).
Papers in Haematologica are published under a Creative Commons license CC BY-NC. According to this license, an article may be copied, displayed, distributed, republished or otherwise reused provided the reuse is not an adaptation or a modification and the integrity of the original paper is maintained. This license does not allow for any kind of commercial use of the paper. For more details, see About Haematologica